[1] 罗佳,金锋.肠道菌群影响宿主行为的研究进展.科学通报,2014,59:2169-2190.
[2] Yu LX,Schwabe RF.The gut microbiome and liver cancer:mechanisms and clinical translation.Nat Rev Gastro-enterol Hepatol,2017,14:527-539.
[3] Sarker S, Gyr K. Non-immunological defence mechanisms of the gut.Gut, 1992,33:987-993.
[4] Neish A. Microbes in gastrointestinal health and disease. Gastroenterology 2009;136:65-80.
[5] Daria Szymanowska-Powaowska, Dorota Orczyk, Katarzyna Leja. Biotechnologicalpotential of Clostridium butyricum bacteria.Brazil J Microbiol,2014, 45:892-901.
[6]Miele L, Marrone G,Lauritano C,et al.Gut-liver axis and microbiota in NAFLD:insight pathophysiology for novel therapeutic target.Curr Pharm Des,2013,19:5314-5324.
[7] 刘露露,王炳元.肠道微生态与酒精性肝病 实用肝脏病杂志,2017 ,20:660-662.
[8] Damaud M,Faivre J,Moniaux N,et a1.Targeting gut flora to prevent progression of hepatoceUular carcinoma.J Hepatol,2013,58:385-387.
[9] 黄晓宇,李刚平,寇继光,等.肝硬化患者肠道菌群失调与Child-Pugh分级的关系.临床肝胆病杂志,2015, 31:392-395.
[10] 赵欣,赵彩彦.肠道菌群失调在慢性肝病发病中的作用研究进展.实用肝脏病杂志,2014,17:106-108.
[11] 盛国光. 肝衰竭患者肠道微生态变化及其干预措施.中西医结合肝病杂志,2016,26:257-259.
[12] 杨福权,唐玉琴,淮文英,等.肠道微生态与疾病发生发展.大家健康,2016,10:2-3.
[13] 赵欣,赵彩彦.肠道菌群失调在慢性肝病发病中的作用研究进展.实用肝脏病杂志,2014,17:106-108.
[14] Wijck K, Verlinden TJM, Eijk HMH et al. Novel multi-sugar assay for ite-specific gastrointestinal permeability analysis: a randomized controlled crossover trial. Clin Nutr,2013,32: 245-251. |
